Armata Pharmaceuticals Announces Presentation of Topline Data From SWARM-P.a. Clinical Study Of AP-PA02 For Chronic Pulmonary Pseudomonas Aeruginosa Infections In Cystic Fibrosis Patients At North American Cystic Fibrosis Conference
Armata Pharmaceuticals Announces Presentation of Topline Data From SWARM-P.a. Clinical Study Of AP-PA02 For Chronic Pulmonary Pseudomonas Aeruginosa Infections In Cystic Fibrosis Patients At North American Cystic Fibrosis Conference
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.